论文部分内容阅读
FDA根据一项最近的临床研究试验结果发布了一个警告,即使用促红细胞生成的药物(E S A)致血红蛋白浓度达到13.5g/dL相比达到11.3g/dL时可显著增加可危及生命的严重心血管合并症。这项发表在2006年11月16日《新英格兰医学杂志》上的“血红蛋白校正和肾功能不全结局的研究”(CHOIR
The FDA issued a warning based on a recent clinical trial that the hemoglobin concentration reached 13.5 g / dL with erythropoietic drugs (ESA) significantly increased the life-threatening heart when compared to 11.3 g / dL Vascular complications. This is published in the November 16, 2006 “New England Journal of Medicine” on the “hemoglobin correction and renal insufficiency outcome of” (CHOIR